Brevan Howard Capital Management
LENZ icon

Brevan Howard Capital Management’s LENZ Therapeutics LENZ Stock Holding History

Brevan Howard Capital Management’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$103K Buy
18,197
+4,627
+34% +$37.3K ﹤0.01% 1986
2026
Q1 		$124K Sell
13,570
-1,838
-12% -$25.8K ﹤0.01% 1990
2025
Q4 		$247K Buy
+15,408
New +$449K ﹤0.01% 1476

Other funds holding LENZ

RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Alpha Wave Global
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

Brevan Howard Capital Management's LENZ Position: Q2 2026 in Review

Brevan Howard Capital Management increased its LENZ Therapeutics (LENZ) stake by 34% in Q2 2026, buying an estimated $37.3K and bringing the position to 18,197 shares worth $103K. The position accounts for ﹤0.01% of the portfolio, ranked #1986.

Brevan Howard Capital Management first reported a position in LENZ in Q4 2025 and has held it in 3 quarters since. The position peaked at $247K in Q4 2025. 145 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

  • Brevan Howard Capital Management held 18,197 shares of LENZ Therapeutics worth $103K as of Q2 2026.
  • Brevan Howard Capital Management bought 4,627 LENZ Therapeutics shares in Q2 2026, an estimated $37.3K.
  • LENZ Therapeutics made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1986 holding.
  • Brevan Howard Capital Management first reported a position in LENZ Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Brevan Howard Capital Management's LENZ Therapeutics position peaked at $247K in Q4 2025.
  • 145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.